Expression of erythropoietin and its receptor in human renal cell carcinoma
2009 (English)In: Tumour Biology, ISSN 1010-4283, E-ISSN 1423-0380, Vol. 30, no 2, 86-92 p.Article in journal (Refereed) Published
Objective: To investigate the prognostic impact of erythropoietin (EPO) and EPO-receptor (EPO-R) expression in tumour as well as serum EPO in patients with renal cell carcinoma (RCC).
Methods: Using immunohistochemistry, EPO and EPO-R were assessed in tissue microarrays from 195 RCCs. RCC type, TNM stage, nuclear grade, survival, EPO and haemoglobin (Hb) levels in blood were registered.
Results: Strong expression of EPO and EPO-R in tumour tissue was found in 83 and 56%, respectively. EPO and EPO-R expression differed between RCC types. Serum EPO and blood Hb did not correlate to the expression of EPO or EPO-R. A positive correlation was found between the expression of EPO and EPO-R (p = 0.028). Survival was not related to tumour EPO, whereas strong EPO-R expression indicated a non-significantly worse prognosis. Serum EPO correlated positively to TNM stage and nuclear grade and negatively to survival. A multivariate analysis showed that TNM stage and nuclear grade were independent prognostic factors. Tumour EPO and EPO-R expression as well as serum EPO added no independent prognostic information.
Conclusion: No correlation between EPO or EPO-R in tumour tissue and serum EPO or blood Hb was found. Neither EPO, EPO-R in tumour tissue nor serum EPO are independent prognostic factors.
Place, publisher, year, edition, pages
2009. Vol. 30, no 2, 86-92 p.
Cancer and Oncology
Research subject Oncology
IdentifiersURN: urn:nbn:se:umu:diva-22455DOI: 10.1159/000216844PubMedID: 19407488OAI: oai:DiVA.org:umu-22455DiVA: diva2:216687